Merck Sharp + Dohme Corp.

Kaleen M Konrad

Michelle R Machacek

Andrew M Haidle

Michael D Altman

Kevin J Wilson

Anna A Zabierek

Jongwon Lim

Jonathan R Young

Ryan D Otte

Tony Siu

Matthew Christopher

Jonathan B Grimm

Brandon Mitsuo Taoka

Paul A Tempest

Kerrie Spencer

Rachel Nicola MacCoss

Hyun Chong Woo

Gabriela De Almeida

Ann Zabierek

Ekundayo Osimboni

The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2). The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 and TYK2 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.

Inhibitors of janus kinases

The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.

The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3, TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.

Inhibitors of Janus kinases

Growing community of inventors

Boston, MA, United States of America

Kaleen M Konrad